A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
Φόρτωση...
Ημερομηνία
Συγγραφείς
Bozionelou, V.
Vamvakas, L.
Pappas, P.
Agelaki, S.
Androulakis, N.
Kalykaki, A.
Nikolaidou, M.
Kentepozidis, N.
Giassas, S.
Marselos, M.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Br J Cancer
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
To determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of pegylated liposomal doxorubicin (PLD), paclitaxel (PCX) and gemcitabine (GEM) combination administered biweekly in patients with advanced solid tumours. Twenty-two patients with advanced-stage solid tumours were treated with escalated doses of PLD on day 1 and PCX plus GEM on day 2 (starting doses: 10, 100 and 800 mg m(-2), respectively) every 2 weeks. DLTs and pharmacokinetic (PK) parameters of all drugs were determined during the first cycle of treatment. All but six (73%) patients had previously received at least one chemotherapy regimen. The DLT dose level was reached at PLD 12 mg m(-2), PCX 110 mg m(-2) and GEM 1000 mg m(-2) with neutropaenia being the dose-limiting event. Of the 86 chemotherapy cycles delivered, grade 3 and 4 neutropaenia occurred in 20% with no cases of febrile neutropaenia. Non-haematological toxicities were mild. The recommended MTDs are PLD 12 mg m(-2), PCX 100 mg m(-2) and GEM 1000 mg m(-2) administered every 2 weeks. The PK data revealed no obvious drug interactions. Biweekly administration of PLD, PCX and GEM is a well-tolerated chemotherapy regimen, which merits further evaluation in various types of solid tumours.
Περιγραφή
Λέξεις-κλειδιά
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse, effects/pharmacokinetics, Deoxycytidine/administration & dosage/*analogs & derivatives/pharmacokinetics, Doxorubicin/administration & dosage/*analogs & derivatives/pharmacology, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms/*drug therapy, Neutropenia/chemically induced, Paclitaxel/*administration & dosage/pharmacokinetics, Polyethylene Glycols/*administration & dosage/pharmacology, Survival Rate
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/17551496
http://www.nature.com/bjc/journal/v97/n1/pdf/6603832a.pdf
http://www.nature.com/bjc/journal/v97/n1/pdf/6603832a.pdf
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής